Literature DB >> 31187846

The pivotal role of MBD4-ATP7B in the human Cu(i) excretion path as revealed by EPR experiments and all-atom simulations.

Zena Qasem1, Matic Pavlin2, Ida Ritacco2, Lada Gevorkyan-Airapetov1, Alessandra Magistrato2, Sharon Ruthstein1.   

Abstract

Copper's essentiality and toxicity require a meticulous mechanism for its acquisition, cellular distribution and excretion, which remains hitherto elusive. Herein, we jointly employed electron paramagnetic resonance spectroscopy and all-atom simulations to resolve the copper trafficking mechanism in humans considering the route travelled by Cu(i) from the metallochaperone Atox1 to the metal binding domains 3 and 4 of ATP7B. Our study shows that Cu(i) in the final part of its extraction pathway is most likely mediated by binding of Atox1 monomer to MBD4 of ATP7B. This interaction takes place through weak metal-stabilized protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31187846     DOI: 10.1039/c9mt00067d

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  3 in total

1.  Copper binding leads to increased dynamics in the regulatory N-terminal domain of full-length human copper transporter ATP7B.

Authors:  Fredrik Orädd; Jonas Hyld Steffen; Pontus Gourdon; Magnus Andersson
Journal:  PLoS Comput Biol       Date:  2022-09-07       Impact factor: 4.779

2.  Cu(I) Controls Conformational States in Human Atox1 Metallochaperone: An EPR and Multiscale Simulation Study.

Authors:  Ortal Perkal; Zena Qasem; Meital Turgeman; Renana Schwartz; Lada Gevorkyan-Airapetov; Matic Pavlin; Alessandra Magistrato; Dan Thomas Major; Sharon Ruthstein
Journal:  J Phys Chem B       Date:  2020-05-22       Impact factor: 2.991

3.  An EPR Study on the Interaction between the Cu(I) Metal Binding Domains of ATP7B and the Atox1 Metallochaperone.

Authors:  Michael Zaccak; Zena Qasem; Lada Gevorkyan-Airapetov; Sharon Ruthstein
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.